About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 160 record(s)
Req # A-2021-00058
Briefing Note: 767605 FINTRAC’s Input to the Follow-up Report of Canada to the Financial Action Task Force (FATF) ;Organization: Financial Transactions and Reports Analysis Centre of Canada
April 2022
Req # A-2021-00076
Obtain a copy of all the official correspondences/letters emails on everything pertaining to the application/administration of the Proceeds of Crime (Money Laundering) and Terrorist Financing Act, including the attached documents, sent or received by Sarah Paquet in her function of Director and Chief Executive Officer (CEO) of CANAFE for the period between July 1, 2021, and November 14, 2021, for the following category: Communication with the Department of Finance CanadaOrganization: Financial Transactions and Reports Analysis Centre of Canada
April 2022
Req # A-2021-10765
Copies of all expense claims and receipts over $ 100.00 for Douglas Clark, Tanya Potashnik and Mitchell Levine. For each expense provide the name of the service provider/contractor, a description of the product or service rendered, the date, and the total amount of the expense. When those three items can not be provided in said format, provide the entirety of records (including receipts, purchase orders, and service contracts) pertaining to the expense.Organization: Patented Medicine Prices Review Board Canada
April 2022
Req # A-2021-10768
Copies of all communications between the PMPRB and Health Canada from May 22, 2021 to June 11, 2021.Organization: Patented Medicine Prices Review Board Canada
April 2022
Req # A-2021-10771
Copies of all emails or logs of media requests or contacts with the PMPRB and Douglas Clark between May 22, 2021 to June 11, 2021.Organization: Patented Medicine Prices Review Board Canada
April 2022
Req # A-2021-00067
FINTRAC Standard Operating Procedures for compliance examinations in effect - November 2021, and Standard Operating Procedures Guide for Compliance Examinations in effect 2020Organization: Financial Transactions and Reports Analysis Centre of Canada
March 2022
Req # A-2021-00069
Compliance MOU between Financial Services Regulatory Authority of Ontario (FSRAO) and Financial Transactions and Reports Analysis Centre of CanadaOrganization: Financial Transactions and Reports Analysis Centre of Canada
March 2022
Req # A-2021-00114
Briefing note: 820736 Approval of Amendment 2021-22 Travel Request for Montreal Relocation ProjectOrganization: Financial Transactions and Reports Analysis Centre of Canada
March 2022
Req # A-2019-00003
•All records concerning or related to the federal government’s Directive on Automated Decision-Making that was prepared by or provided to the PMPRB. (January 1, 2019 to May 2, 2019). •A list of all pending access to information requests at the PMPRB (as of May 2, 2019). •All records relating to the impact of the pending amendments on national pharmacare or the impact of national pharmacare on the pending amendments (From May 2, 2019 to March 1, 2022). •The agenda and minutes for any meetings held by PMPRB executives between January 1, 2018 and May 1, 2019 that concerned the pending amendments. •All revisions or redrafts of the Regulatory Impact Analysis Statement (date of my first request to May 2, 2019). •All records relating to the new basket of countries under the pending amendments, including the inclusion or exclusion of particular countries (date of my first request down to May 2, 2019). •All records relating to the adoption of new pricing factors under the pending amendments (date of my first request down to May 2, 2019). •All records relating to changes in the reporting requirements for patentees under the pending amendments, especially the requirement to report confidential discounts or rebates (date of my first request down to May 2, 2019). •All records relating to a possible decision to distinguish between existing and new medicines in the application of the pending regulations (whether concerning pricing rules, reporting requirements, or any other legal obligation) (date of my first request down to May 2, 2019). •All studies, reports, or other documents prepared by or held by the PMPRB which deal with changes to the content of the pending regulations or the guidelines which are being developed (date of my first request down to May 2, 2019). •All communications regarding the proposed amendments between the PMPRB and one or more of the following organizations: Health Canada, ISED, or CIPO (date of my first request down to May 2, 2019). •All letters or other communications received between September 1, 2018 and May 1, 2019 that question or criticize the pending amendments (date of my first request down to May 2, 2019). •All records generated by the PMPRB or another federal government entity that comment on or analyze the report prepared by Mr. David Dodge (August 23, 2018 to May 2, 2019). •A copy of all training presentations concerning the pending amendments that were held or were supposed to be held between Setptember 1, 2019 and May 1, 2019.Organization: Patented Medicine Prices Review Board Canada
March 2022
Req # A-2022-05127
Copies of all emails to/from Douglas Clark, Melanie Bourassa-Forcier, Tanya Potashnik and Health Canada officials from November 1, 2021 to January 31, 2022.Organization: Patented Medicine Prices Review Board Canada
March 2022